168 related articles for article (PubMed ID: 7579429)
21. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
Sella A; Kilbourn RG; Gray I; Finn L; Zukiwski AA; Ellerhorst J; Amato RJ; Logothetis CJ
Cancer Biother; 1994; 9(2):103-11. PubMed ID: 7812360
[TBL] [Abstract][Full Text] [Related]
23. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study.
Gill PS; Espina BM; Moudgil T; Kidane S; Esplin JA; Tulpule A; Levine AM
Leukemia; 1994; 8 Suppl 3():S26-32. PubMed ID: 7808021
[TBL] [Abstract][Full Text] [Related]
24. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
[TBL] [Abstract][Full Text] [Related]
25. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
27. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
28. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
30. Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Poiesz BJ; Comis RL
J Biol Response Mod; 1989 Aug; 8(4):359-65. PubMed ID: 2666585
[TBL] [Abstract][Full Text] [Related]
31. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.
Khatri VP; Baiocchi RA; Bernstein ZP; Caligiuri MA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S129-36. PubMed ID: 9457408
[TBL] [Abstract][Full Text] [Related]
33. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection.
Hersh EM; Murray JL; Hong WK; Rosenblum MG; Reuben JM; Weilbaecher R; Sarwal AN; Bradley EC; Konrad M; Arnett FC
Biotherapy; 1989; 1(3):215-26. PubMed ID: 2642025
[TBL] [Abstract][Full Text] [Related]
35. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.
Degrate L; Nobili C; Franciosi C; Caprotti R; Brivio F; Romano F; Leone BE; Trezzi R; Uggeri F
Langenbecks Arch Surg; 2009 Jan; 394(1):115-21. PubMed ID: 18670745
[TBL] [Abstract][Full Text] [Related]
38. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
39. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.
Klatte T; Ittenson A; Röhl FW; Ecke M; Allhoff EP; Böhm M
Br J Cancer; 2006 Nov; 95(9):1167-73. PubMed ID: 17031403
[TBL] [Abstract][Full Text] [Related]
40. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion.
Klimas N; Patarca R; Walling J; Garcia R; Mayer V; Moody D; Okarma T; Fletcher MA
AIDS; 1994 Aug; 8(8):1073-81. PubMed ID: 7986402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]